Brimonidine tartrate 0.15% drops to reduce low post-LASIK residual myopia: A retrospective study.
<h4>Purpose</h4>Residual myopia following Laser-assisted in situ keratomileusis (LASIK) surgery poses a significant concern, with existing literature extensively detailing the use of timolol for treatment. This study aims to assess prediction factors for brimonidine tartrate 0.15% (Alpha...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0329364 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849684346155302912 |
|---|---|
| author | Nir Gomel Asaf Achiron Nadav Shemesh Elad Eilon Tal Yahalomi Dana Barequet Nadav Levinger Dafi Porat Shmuel Levinger Ami Hirsch Nir Sorkin Eliya Levinger |
| author_facet | Nir Gomel Asaf Achiron Nadav Shemesh Elad Eilon Tal Yahalomi Dana Barequet Nadav Levinger Dafi Porat Shmuel Levinger Ami Hirsch Nir Sorkin Eliya Levinger |
| author_sort | Nir Gomel |
| collection | DOAJ |
| description | <h4>Purpose</h4>Residual myopia following Laser-assisted in situ keratomileusis (LASIK) surgery poses a significant concern, with existing literature extensively detailing the use of timolol for treatment. This study aims to assess prediction factors for brimonidine tartrate 0.15% (Alphagan-P) response on post-LASIK residual myopic refraction reduction.<h4>Methods</h4>The study included consecutive patients who received Alphagan-P during their follow-up for post-LASIK residual myopia.<h4>Results</h4>We included 61 patients (55% male) with a mean age of 35.18 ± 10.13 Alphagan-P Treatment started at a mean of 4.94 ± 5.64 months after surgery for residual myopia of -0.53 ± 0.71D. Comparison analysis of patients who responded (n = 32, 51.6%) to patients who did not (n = 30, 48.4%) shows that responders were older (38.1 ± 9.1 vs. 32.3 ± 10.3, p = 0.03), had higher baseline myopic Spherical equivalent (SE, -0.82 ± 0.65 vs. -0.26 ± 0.66 p < 0.01), and lower uncorrected visual acuity (Uncorrected visual acuity [UCVA], 0.14 ± 0.2 vs. -0.003 ± 0.12 p = 0.01). Multiple Binary logistic regression confirmed these predictors for response (UCVA (OR=70.6, P = .006), larger SE (OR=3.8, P = .004,) and older age (OR=1.06, P = .03)).<h4>Conclusions</h4>Alphagan-P can reduce up to 0.5D of post-LASIK residual myopia in roughly 50% of subjects. This treatment might be recommended to fine-tune outcomes for low residual myopia. |
| format | Article |
| id | doaj-art-30e46265d5ff4667ae0de6632b4e3d4c |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-30e46265d5ff4667ae0de6632b4e3d4c2025-08-20T03:23:30ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01207e032936410.1371/journal.pone.0329364Brimonidine tartrate 0.15% drops to reduce low post-LASIK residual myopia: A retrospective study.Nir GomelAsaf AchironNadav ShemeshElad EilonTal YahalomiDana BarequetNadav LevingerDafi PoratShmuel LevingerAmi HirschNir SorkinEliya Levinger<h4>Purpose</h4>Residual myopia following Laser-assisted in situ keratomileusis (LASIK) surgery poses a significant concern, with existing literature extensively detailing the use of timolol for treatment. This study aims to assess prediction factors for brimonidine tartrate 0.15% (Alphagan-P) response on post-LASIK residual myopic refraction reduction.<h4>Methods</h4>The study included consecutive patients who received Alphagan-P during their follow-up for post-LASIK residual myopia.<h4>Results</h4>We included 61 patients (55% male) with a mean age of 35.18 ± 10.13 Alphagan-P Treatment started at a mean of 4.94 ± 5.64 months after surgery for residual myopia of -0.53 ± 0.71D. Comparison analysis of patients who responded (n = 32, 51.6%) to patients who did not (n = 30, 48.4%) shows that responders were older (38.1 ± 9.1 vs. 32.3 ± 10.3, p = 0.03), had higher baseline myopic Spherical equivalent (SE, -0.82 ± 0.65 vs. -0.26 ± 0.66 p < 0.01), and lower uncorrected visual acuity (Uncorrected visual acuity [UCVA], 0.14 ± 0.2 vs. -0.003 ± 0.12 p = 0.01). Multiple Binary logistic regression confirmed these predictors for response (UCVA (OR=70.6, P = .006), larger SE (OR=3.8, P = .004,) and older age (OR=1.06, P = .03)).<h4>Conclusions</h4>Alphagan-P can reduce up to 0.5D of post-LASIK residual myopia in roughly 50% of subjects. This treatment might be recommended to fine-tune outcomes for low residual myopia.https://doi.org/10.1371/journal.pone.0329364 |
| spellingShingle | Nir Gomel Asaf Achiron Nadav Shemesh Elad Eilon Tal Yahalomi Dana Barequet Nadav Levinger Dafi Porat Shmuel Levinger Ami Hirsch Nir Sorkin Eliya Levinger Brimonidine tartrate 0.15% drops to reduce low post-LASIK residual myopia: A retrospective study. PLoS ONE |
| title | Brimonidine tartrate 0.15% drops to reduce low post-LASIK residual myopia: A retrospective study. |
| title_full | Brimonidine tartrate 0.15% drops to reduce low post-LASIK residual myopia: A retrospective study. |
| title_fullStr | Brimonidine tartrate 0.15% drops to reduce low post-LASIK residual myopia: A retrospective study. |
| title_full_unstemmed | Brimonidine tartrate 0.15% drops to reduce low post-LASIK residual myopia: A retrospective study. |
| title_short | Brimonidine tartrate 0.15% drops to reduce low post-LASIK residual myopia: A retrospective study. |
| title_sort | brimonidine tartrate 0 15 drops to reduce low post lasik residual myopia a retrospective study |
| url | https://doi.org/10.1371/journal.pone.0329364 |
| work_keys_str_mv | AT nirgomel brimonidinetartrate015dropstoreducelowpostlasikresidualmyopiaaretrospectivestudy AT asafachiron brimonidinetartrate015dropstoreducelowpostlasikresidualmyopiaaretrospectivestudy AT nadavshemesh brimonidinetartrate015dropstoreducelowpostlasikresidualmyopiaaretrospectivestudy AT eladeilon brimonidinetartrate015dropstoreducelowpostlasikresidualmyopiaaretrospectivestudy AT talyahalomi brimonidinetartrate015dropstoreducelowpostlasikresidualmyopiaaretrospectivestudy AT danabarequet brimonidinetartrate015dropstoreducelowpostlasikresidualmyopiaaretrospectivestudy AT nadavlevinger brimonidinetartrate015dropstoreducelowpostlasikresidualmyopiaaretrospectivestudy AT dafiporat brimonidinetartrate015dropstoreducelowpostlasikresidualmyopiaaretrospectivestudy AT shmuellevinger brimonidinetartrate015dropstoreducelowpostlasikresidualmyopiaaretrospectivestudy AT amihirsch brimonidinetartrate015dropstoreducelowpostlasikresidualmyopiaaretrospectivestudy AT nirsorkin brimonidinetartrate015dropstoreducelowpostlasikresidualmyopiaaretrospectivestudy AT eliyalevinger brimonidinetartrate015dropstoreducelowpostlasikresidualmyopiaaretrospectivestudy |